Skip to main content

Table 7 Arrangement by the tumor sites in each Group

From: Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience

Primary Site Group I Group II Group III Group IV Group V
CCCA SCA ENAdCA MxSEAdCA Other
  n HER2+ n HER2+ n HER2+ n HER2+ n HER2+
Endometrium 6 2 (33.3 %) 9 4 (44.4 %) 22   11 1 (9.1 %) 10 1 (10.0 %)
Ovary 5 1 (20.0 %) 30 1 (3.3 %) 5   13   3  
Fallopian Tube    1   1      
Peritoneum    5     1    
Pelvic Mass        1   1  
Cervix          1  
All Sites 11 3 (27.3 %) 45 5 (11.1 %) 28 0 (0.0 %) 26 1 (3.9 %) 15 1 (6.7 %)
  1. Bold data signify the positive results
  2. CCCA clear cell carcinoma, SCA serous carcinoma, ENAdCA endometrioid adenocarcinoma, MxSEAdCA mixed surface epithelial adenocarcinoma, Other other neoplasms, HER2+ positive HER2/neu